Novo Nordisk (NVO.N) raised its 2026 adjusted sales and adjusted operations profit guidance but still expects fiscal-year adjusted EBIT growth of -6% to 0%. Q2 2026 adjusted sales rose 7% at constant exchange rates (CER); adjusted operating profit ro

2026-08-05

Novo Nordisk (NVO.N) raised its 2026 adjusted sales and adjusted operations profit guidance but still expects fiscal-year adjusted EBIT growth of -6% to 0%. Q2 2026 adjusted sales rose 7% at constant exchange rates (CER); adjusted operating profit rose 11% CER.